Stock events for CareDx, Inc. (CDNA)
CareDx's stock has experienced volatility in the past six months. Key events impacting the stock include the Q4 2025 earnings report, which showed revenue exceeding estimates but EPS missing estimates, analyst rating changes with mixed opinions, insider selling by the CEO, and the stock price moving below its 50-day moving average, indicating a potential downward trend.
Demand Seasonality affecting CareDx, Inc.’s stock price
CareDx's products and services exhibit some demand seasonality, with a seasonality score of -18. March has historically been a "red month" for the stock. Q3 2025 testing volumes experienced seasonal slowdowns and fell short of expectations.
Overview of CareDx, Inc.’s business
CareDx, Inc. is a precision medicine company focused on improving outcomes for transplant patients. It operates in the healthcare sector, specifically in diagnostics, research, biotechnology, and health technology. The company develops and commercializes healthcare solutions for transplant patients, offering testing services, products, and digital solutions throughout the transplant journey. Major products and services include AlloSure Kidney, AlloMap Heart, AlloSure Heart, AlloSure Lung, HeartCare, HistoMap Kidney, AlloHeme, QTYPE, Olerup SSP, Ottr, AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, Allocell, and other software solutions.
CDNA’s Geographic footprint
CareDx, Inc. provides solutions in the United States and internationally, generating the majority of its revenue from the United States. It serves transplant centers across the United States, Europe, and select international markets.
CDNA Corporate Image Assessment
CareDx generally maintains a reputation as a leader in precision medicine for transplant patients. Analyst sentiment is cautiously optimistic, with a consensus rating of "Hold." The company has faced challenges in translating revenue growth into profitability. Continuous innovation and strategic partnerships bolster its reputation.
Ownership
CareDx's ownership is diversified among institutional investors, company insiders, and the public market. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Bamco Inc /ny/. Neil Gagnon is the largest individual shareholder, and John Walter Hanna Jr. (CEO) also owns a significant number of shares.
